|
 |
European Pharmaceutical Contractor
|
A recent publication, Cancer 2025: The Future of Cancer Care (1), reported the results of a conference of 60 eminent oncologists, health care planners, legislators, economists and patients. The predictions from this meeting with respect to the delivery of cancer care in the future are that:
More patients will get cancer due to the ageing of the population
There will be an increase in the early diagnosis of cancer due to the advent of one stop clinics offering imaging and tumour marker services
Screening for genetic predisposition and contact with environmental carcinogenic hazards will be routine and continuous - in some instances facilitated via signalling from implanted subcutaneous chip monitoring devices
Chemoprevention will be automatic on discovery of premalignant genetic signatures - similar to current usage of Tamoxifen in the prevention of breast cancer in women at high risk
The use of vaccines, such as those directed against hpv16 to prevent cancer of the cervix, will become standard
Treatment of cancer will include minimally invasive surgery - frequently performed by robotics and accompanied by intra operative physical therapy such as electrons, lasers or radionuclides
Radiotherapy will most likely be given by accelerated schemes in doses driven by the genomics of an individual tumour compared with the patient's normal tissues - robotics, distance CT/PET planning, radiosensitisers and intelligent radionuclide targeting will be utilised
Systemic treatment will be dictated by genomic/proteomic signatures of the patient's normal tissues, allowing for the pharmacogenomic advantages of certain drugs and the patient's tumour signatures to dictate the specific targeted molecules that will best fit the particular tumour
The majority of anticancer drugs will be oral and will be delivered near or at the patient's home - monitoring of blood counts and toxicity will be less of an issue as targeted compounds will not produce the classic widespread damage typical of current day cytotoxics
Follow-up will be minimally invasive and exploit artificial intelligence networks
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Professor Gordon McVie, Oncology Advisor at Inveresk
Professor Gordon McVie MD, FRCP, FRCPS, FRCSE, FMedSci, DSc (Hons) is widely regarded as a leading international authority in the research and treatment of cancer. He is currently Director of Cancer Intelligence, an advisory body to biotechnology and pharmaceutical companies, investors, the media and cancer patients. He is a Visiting Professor at Glasgow University, Scotland; honorary Consultant in Medical Oncology at the Welsh Cancer Institute, Cardiff; Clinical Research Director at the European Institute of Oncology, Milan; and Oncology Advisor to Inveresk. Previously Professor McVie was Chief Executive of the Cancer Research Campaign (CRC). He has authored almost 300 peer-reviewed articles, contributed to over 35 books and is currently European Editor for the US Journal of the National Cancer Institute.
|
|
|
|
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
